期刊
TRENDS IN ENDOCRINOLOGY AND METABOLISM
卷 21, 期 3, 页码 123-133出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2009.12.003
关键词
-
资金
- NATIONAL CANCER INSTITUTE [R01CA075979] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA075979, R01 CA075979-10] Funding Source: Medline
Somatotropin-release inhibitory factor (SRIF) is a major regulator of pituitary function, mostly inhibiting hormone secretion and to a lesser extent pituitary cell growth. Five SRIF receptor subtypes (SSTR1-5) are ubiquitously expressed G-protein coupled receptors. In the pituitary, SSTR1, 2, 3 and 5 are expressed, with SSTR2 and SSTR5 predominating. As new SRIF analogs have recently been introduced for treatment of pituitary disease, we evaluate the current knowledge of cell-specific pituitary SRIF receptor signaling and highlight areas of future research for comprehensive understanding of these mechanisms. Elucidating pituitary SRIF receptor signaling enables understanding of pituitary hormone secretion and cell growth, and also encourages future therapeutic development for pituitary disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据